Dr. Yang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4100 John R St
Detroit, MI 48201Phone+1 800-527-6266Fax+1 313-831-4065- Is this information wrong?
Education & Training
Ascension Providence/MSUCHMFellowship, Hematology and Medical Oncology, 2008 - 2011- Ascension Providence/MSUCHMResidency, Internal Medicine, 2005 - 2008
- Ascension Providence/MSUCHMInternship, Transitional Year, 2004 - 2005
University of Michigan Medical SchoolClass of 1998
Certifications & Licensure
MI State Medical License 2004 - 2026- American Board of Internal Medicine Hematology
Clinical Trials
- Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation Start of enrollment: 2021 Nov 11
- A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies Start of enrollment: 2020 Aug 07
- A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2022 Dec 12
- Join now to see all
Publications & Presentations
PubMed
- Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.Hurrish, K., Su, Y., Patel, S., Ramage, C., Zhao, J., Temby, B., Carter, J., Edwards, H., Buck, S., Wiley, S., Hüttemann, M., Polin, L., Kushner, J., Dzinic, S., White...> ;Biochemical Pharmacology. 2024 Feb 1
- 2 citationsAcquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.Jenna L Carter, Yongwei Su, Xinan Qiao, Jianlei Zhao, Guan Wang, Mackenzie Howard, Holly Edwards, Xun Bao, Jing Li, Maik Hüttemann, Jay Yang, Jeffrey W Taub, Yubin Ge> ;Biochemical Pharmacology. 2023 Oct 1
- Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis.Katie H Hurrish, Yongwei Su, Shraddha Patel, Cassandra L Ramage, Jenna L Carter, Holly Edwards, Steven A Buck, Sandra E Wiley, Maik Hüttemann, Lisa Polin, Juiwanna Kus...> ;Research Square. 2023 Apr 28
- Join now to see all
Abstracts/Posters
- Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Na¥ve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive...Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
What Is Leukemia? Symptoms, Causes and TreatmentJune 23rd, 2023
Hospital Affiliations
Karmanos Cancer CenterDetroit, Michigan
DMC Harper University HospitalDetroit, Michigan
DMC Detroit Receiving Hospital & University Health CenterDetroit, Michigan
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
